Effect of single and multiple doses of sulphinpyrazone on antipyrine metabolism and urinary excretion of 6-beta-hydroxycortisol

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00542523PMID 6141054
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Induction of drug metabolizing enzymes by sulfinpyrazone

  2004influential reference
• Stereoselective Interaction of Sulfinpyrazone with Racemic Warfarin and Its Separated Enantiomorphs in Man

  1982cited by this paper
• Differential effects of enzyme induction on antipyrine metabolite formation.

  1982cited by this paper
• Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity.

  1981cited by this paper
• Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function.

  1980cited by this paper
• New metabolites of sulfinpyrazone in man.

  1980cited by this paper
• Sulfinpyrazone in the prevention of sudden death after myocardial infarction.

  1980cited by this paper
• A Rapid and Sensitive Method for the Determination of Phenazone (Antipyrine®) using Gas-Liquid-Chromatography with Nitrogen Detection

  1980cited by this paper
• Two new metabolites of sulfinpyrazone in the rabbit: a possible cause of the prolonged in vivo effect.

  1979cited by this paper
• Measurement of urinary 6-β-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin

  1979cited by this paper
• Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man.

  1979cited by this paper
• A direct radioimmunoassay for 6β-hydroxycortisol in human urine

  1978cited by this paper
• A direct radioimmunoassay for 6 beta-hydroxycortisol in human urine.

  1978cited by this paper
• Platelets, Drugs and Longevity in a Geriatric Population

  1975cited by this paper
• Urinary 17-hydroxycorticosteroid determination with p-hydrazinobenzenesulfonic acid-phosphoric acid.

  1973cited by this paper
• THE EFFECT OF SULFINPYRAZONE (ANTURAN) ON PLATELET ECONOMY AND BLOOD COAGULATION IN MAN.

  1965cited by this paper

• Candidate Proficiency Test Chemicals to Address Industrial Chemical Applicability Domains for in vitro Human Cytochrome P450 Enzyme Induction

  2022cites this paper
• Validation of in vitro methods for human cytochrome P450 enzyme induction: Outcome of a multi-laboratory study

  2019cites this paper
• Quantitative evaluation of hepatic and intestinal induction of CYP3A in clinical practice

  2019cites this paper
• Physiological scaling factors and mechanistic models for prediction of renal clearance from in vitro data

  2016cites this paper
• Induction of cytochrome P450 enzymes: a view on human in vivo findings

  2012cites this paper
• Utility of DPX 2 Cells for Predicting CYP 3 A Induction-Mediated Drug-Drug Interactions and Associated Structure-Activity Relationships

  2012cites this paper
• UNIWERSYTET MEDYCZNY IM. KAROLA MARCINKOWSKIEGO W P OZNANIU KATEDRA I ZAKËAD FARMACJI KLINICZNEJ I BIOFARMACJI PRACOWNIA FARMAKOGENETYKI DOŚWIADCZALNEJ

  2010cites this paper
• Inhibition and induction of human cytochrome P450 enzymes: current status

  2008cites this paper
• Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment

  2004cites this paper
• Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol

  2004cites this paper
• Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

  2003cites this paper
• Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

  2003cites this paper
• Antipyrine as a model drug substance to assess oxidative metabolism.

  1994cites this paper
• Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.

  1993cites this paper
• The model drug approach in clinical pharmacology

  1991cites this paper
• Antipyrine elimination and hepatic microsomal enzyme activity in patients with liver disease

  1990cites this paper
• Assessment of enzyme induction and enzyme inhibition in humans: toxicological implications.

  1990cites this paper
• Increased 6-Hydroxycortisol Excretion in Pregnant Women: Implication of Drug-Metabolizing Enzyme Induction

  1990cites this paper
• [Evaluation of liver monooxygenase function by the kinetics of antipyrine and its metabolites in liquid media of the body].

  1989cites this paper
• Antipyrine as a model drug to study hepatic drug-metabolizing capacity.

  1988cites this paper
• [Monooxigenase activity in liver diseases (study based on data of antipyrine metabolism)].

  1987cites this paper
• The urinary 6 beta-hydroxycortisol excretion in man on inducers and inhibitors of the hepatic mixed function oxidase.

  1987cites this paper
• [Possibilities of evaluating the activity of the drug biotransformation system in clinical pharmacology].

  1987cites this paper
• Pharmacokinetics and Reversible Biotransformation of Sulfinpyrazone and Its Metabolites in Rabbits. II. Multiple-Dose Study

  1986cites this paper
• Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.

  1985cites this paper
• Simultaneous determination of antipyrine and metabolites in human plasma and urine by high-performance liquid chromatography.

  1984cites this paper